About Cempra
Cempra is a company based in Chapel Hill (United States) founded in 2006. Cempra has raised $149.5 million across 8 funding rounds from investors including Fujifilm, Cubist Pharmaceuticals and Ontario Teachers' Pension Plan. The company has 78 employees as of December 31, 2015. Cempra operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Chapel Hill, United States
- Employees 78 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cempra Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$149.5 M (USD)
in 8 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Sep 09, 2014
-
Investors
Fujifilm
& 6 more
-
Employee Count
78
as on Dec 31, 2015
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cempra
Unlock access to complete
Unlock access to complete
Funding Insights of Cempra
Cempra has successfully raised a total of $149.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cempra
Cempra has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fujifilm, Cubist Pharmaceuticals and Ontario Teachers' Pension Plan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Early-stage life sciences and tech focused VC firm funding companies in the US
|
Locked | Locked | Locked |
Investor details for Cempra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cempra
Investment portfolio details for Cempra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cempra
Detailed financials for Cempra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cempra Comparisons
Peer comparison for Cempra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cempra
Cempra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of Cempra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cempra
Complete news archive for Cempra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cempra
Cempra was founded in 2006.
Cempra is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
Cempra is a funded company, having raised a total of $149.5M across 8 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Cempra is 78.
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products - Solithromycin (CEM-101) and TAKSTA (CEM-102, Sodium Fusidate), both in clinical-stage development, address the need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
Cempra's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Cempra has 7 investors. Key investors include Fujifilm, Cubist Pharmaceuticals, Ontario Teachers' Pension Plan, Quaker Partners, and Devon Park BioVentures.